Jazz Pharmaceuticals PLC
JAZZHealthcare|Biotechnology|Ireland
$243.79
-3.09 (-1.25%)
DCF (FCF)
$213.42
Earnings Power
$74.91
Financials
Financial Snapshot
Market Cap
$15.31B
Enterprise Value
$-2.54B
Revenue (TTM)
$4.44B
Net Income (TTM)
$29.5M
Cash & Equivalents
—
Net Cash/Share
$-71.02
Free Cash Flow (TTM)
$1.14B
Operating CF (TTM)
$1.33B
Debt/Equity
1.2
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $426.0M | $601.0M | $824.6M | $1.08B | $2.13B | $591.4M | $881.5M | $1.63B | $2.99B | $2.44B | $2.87B | |
| Operating Cash Flow | $592.4M | $693.1M | $798.9M | $776.4M | $899.6M | $778.5M | $1.27B | $1.09B | $1.40B | $1.36B | $1.33B | |
| Free Cash Flow | $409.0M | $579.1M | $667.4M | $594.1M | $520.4M | $733.0M | $773.8M | $1.05B | $1.35B | $1.15B | $1.14B | |
| Capital Expenditure | $-183.4M | $-114.0M | $-131.5M | $-182.3M | $-379.3M | $-45.5M | $-498.2M | $-43.0M | $-48.1M | $-209.8M | $-190.6M | |
| Financing Cash Flow | $541.0M | $-409.1M | $-479.1M | $-293.7M | $528.1M | $3.97B | $-529.5M | $-305.3M | $20.5M | $-873.4M | $-138.4M |
R&D Spending
R&D (TTM)
$798.1M
R&D Intensity
18.0%
R&D Growth YoY
+2.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49B | $1.62B | $1.89B | $2.16B | $2.36B | $3.09B | $3.66B | $3.83B | $4.07B | $4.27B | $4.44B | |
| R&D Expense | $162.3M | $198.4M | $226.6M | $299.7M | $335.4M | $505.7M | $590.5M | $849.7M | $884.0M | $782.7M | $798.1M | |
| R&D % of Revenue | 10.9% | 12.3% | 12.0% | 13.9% | 14.2% | 16.3% | 16.1% | 22.2% | 21.7% | 18.3% | 18.0% | |
| SG&A | $502.9M | $544.2M | $683.5M | $736.9M | $854.2M | $1.45B | $1.42B | $1.34B | $1.39B | $1.81B | $1.65B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49B | $1.62B | $1.89B | $2.16B | $2.36B | $3.09B | $3.66B | $3.83B | $4.07B | $4.27B | $4.44B | |
| Cost of Goods Sold | $105.4M | $110.2M | $121.5M | $127.9M | $148.9M | $440.8M | $540.5M | $435.6M | $445.7M | $503.3M | $532.8M | |
| Gross Profit | $1.38B | $1.51B | $1.77B | $2.03B | $2.21B | $2.65B | $3.12B | $3.40B | $3.62B | $3.76B | $3.91B | |
| R&D | $162.3M | $198.4M | $226.6M | $299.7M | $335.4M | $505.7M | $590.5M | $849.7M | $884.0M | $782.7M | $798.1M | |
| SG&A | $502.9M | $544.2M | $683.5M | $736.9M | $854.2M | $1.45B | $1.42B | $1.34B | $1.39B | $1.81B | $1.65B | |
| Operating Income | $615.4M | $613.8M | $657.7M | $642.3M | $765.5M | $170.3M | $512.3M | $597.6M | $726.6M | $517.6M | $910.1M | |
| Interest Expense | $-61.9M | $-77.8M | $-78.5M | $-72.3M | $-99.7M | $-278.8M | $-288.2M | $-289.4M | $-238.1M | $-195.1M | $-181.2M | |
| Pretax Income | $532.4M | $441.1M | $529.5M | $454.3M | $275.1M | $-112.8M | $-372.8M | $297.9M | $470.4M | $-627.9M | $-218.8M | |
| Net Income | $396.8M | $487.8M | $447.1M | $523.4M | $238.6M | $-329.7M | $-224.1M | $414.8M | $560.1M | $-356.1M | $29.5M | |
| EPS (Diluted) | 6.41 | 7.96 | 7.30 | 9.09 | 4.22 | -5.52 | -3.58 | 6.10 | 8.65 | -5.84 | -0.02 | |
| EBITDA | $708.2M | $684.0M | $824.7M | $896.7M | $653.1M | $718.4M | $544.9M | $1.23B | $1.37B | $263.5M | $675.3M | |
| Shares Out. (M) | 61.87 | 61.32 | 61.22 | 57.55 | 56.52 | 59.69 | 62.54 | 72.07 | 66.01 | 60.98 | 66.10 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $366.0M | $386.0M | $309.6M | $637.3M | $1.06B | $591.4M | $881.5M | $1.51B | $2.41B | $1.39B | $1.84B | |
| Marketable Securities | $60.0M | $215.0M | $515.0M | $440.0M | $1.07B | $0.00 | $0.00 | $120.0M | $580.0M | $1.05B | $1.03B | |
| Total Current Assets | $748.1M | $968.3M | $1.23B | $1.63B | $2.84B | $2.61B | $2.61B | $3.44B | $4.63B | $4.17B | $4.58B | |
| Total Assets | $4.80B | $5.12B | $5.20B | $5.54B | $6.54B | $12.30B | $10.84B | $11.39B | $12.01B | $11.66B | $11.86B | |
| Total Current Liabilities | $257.4M | $293.9M | $345.5M | $364.5M | $653.7M | $809.3M | $933.2M | $1.54B | $1.04B | $2.24B | $2.25B | |
| Long-Term Debt | $1.99B | $1.54B | $1.56B | $1.57B | $1.85B | $6.02B | $5.69B | $5.11B | $6.08B | $4.33B | $4.32B | |
| Total Liabilities | $2.92B | $2.41B | $2.45B | $2.43B | $2.88B | $8.33B | $7.75B | $7.66B | $7.92B | $7.34B | $7.33B | |
| Stockholders' Equity | $1.88B | $2.71B | $2.76B | $3.11B | $3.66B | $3.97B | $3.09B | $3.74B | $4.09B | $4.32B | $4.53B | |
| Retained Earnings | $528.9M | $918.0M | $841.0M | $1.07B | $1.16B | $830.2M | $733.6M | $878.7M | $1.13B | $646.2M | $939.2M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $592.4M | $693.1M | $798.9M | $776.4M | $899.6M | $778.5M | $1.27B | $1.09B | $1.40B | $1.36B | $1.33B | |
| Capital Expenditure | $-183.4M | $-114.0M | $-131.5M | $-182.3M | $-379.3M | $-45.5M | $-498.2M | $-43.0M | $-48.1M | $-209.8M | $-190.6M | |
| Free Cash Flow | $409.0M | $579.1M | $667.4M | $594.1M | $520.4M | $733.0M | $773.8M | $1.05B | $1.35B | $1.15B | $1.14B | |
| Investing Cash Flow | $-1.75B | $-268.9M | $-394.5M | $-155.3M | $-1.01B | $-5.21B | $-446.2M | $-163.1M | $-508.2M | $-1.51B | $-1.22B | |
| Financing Cash Flow | $541.0M | $-409.1M | $-479.1M | $-293.7M | $528.1M | $3.97B | $-529.5M | $-305.3M | $20.5M | $-873.4M | $-138.4M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $-278.3M | $-98.8M | $-523.7M | $-301.4M | $-146.5M | $0.00 | $-54.0K | $-269.8M | $-311.4M | $-125.0M | $0.00 | |
| Issuance of Debt | $994.6M | $559.4M | $0.00 | $0.00 | $1.48B | $5.19B | $0.00 | $0.00 | $980.8M | $0.00 | $0.00 | |
| Payments of Debt | $-178.3M | $-886.1M | $-25.7M | $-33.4M | $-889.6M | $-1.32B | $-582.0M | $-31.0M | $-606.0M | $-781.0M | $-31.0M | |
| Stock Based Comp. | $98.8M | $106.9M | $102.4M | $110.6M | $121.0M | $189.0M | $222.0M | $226.8M | $248.0M | $291.1M | $297.9M | |
| Net Change in Cash | $-622.8M | $20.1M | $-76.4M | $327.7M | $420.4M | $-466.3M | $290.0M | $624.8M | $906.6M | $-1.02B | $-17.6M |
Dilution Tracker
Shares Outstanding
66M
5-Year Share Growth
+10.7%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 61.87 | 61.32 | 61.22 | 57.55 | 56.52 | 59.69 | 62.54 | 72.07 | 66.01 | 60.98 | 66.10 | |
| YoY Change % | — | -0.9% | -0.2% | -6.0% | -1.8% | 5.6% | 4.8% | 15.2% | -8.4% | -7.6% | 8.4% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $-278.3M | $-98.8M | $-523.7M | $-301.4M | $-146.5M | $0.00 | $-54.0K | $-269.8M | $-311.4M | $-125.0M | $0.00 | |
| Stock Based Comp. | $98.8M | $106.9M | $102.4M | $110.6M | $121.0M | $189.0M | $222.0M | $226.8M | $248.0M | $291.1M | $297.9M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 92.9% | 93.2% | 93.6% | 94.1% | 93.7% | 85.8% | 85.2% | 88.6% | 89.0% | 88.2% | 88.0% | |
| Operating Margin % | 41.4% | 37.9% | 34.8% | 29.7% | 32.4% | 5.5% | 14.0% | 15.6% | 17.9% | 12.1% | 20.5% | |
| Net Margin % | 26.7% | 30.1% | 23.6% | 24.2% | 10.1% | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% | 0.7% | |
| EBITDA Margin % | 47.6% | 42.3% | 43.6% | 41.5% | 27.6% | 23.2% | 14.9% | 32.0% | 33.6% | 6.2% | 15.2% | |
| FCF Margin % | 27.5% | 35.8% | 35.3% | 27.5% | 22.0% | 23.7% | 21.1% | 27.4% | 33.1% | 26.9% | 25.8% | |
| ROE % | 22.8% | 21.3% | 16.3% | 17.8% | 7.0% | -8.6% | -6.4% | 12.2% | 14.3% | -8.5% | 0.7% | |
| ROA % | 9.8% | 9.8% | 8.7% | 9.7% | 4.0% | -3.5% | -1.9% | 3.7% | 4.8% | -3.0% | 0.3% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 20.30 / 193.67
Industry Med.27.41
P/S3.43
Historical1.53 / 3.04 / 6.76
Industry Med.9.51
P/B3.37
Historical1.44 / 2.58 / 5.40
Industry Med.2.93
EV/EBITDA26.44
Historical6.91 / 14.41 / 77.90
Industry Med.13.14
EV/Revenue4.02
Historical2.17 / 4.12 / 7.34
Industry Med.8.71
P/FCF13.41
Historical4.17 / 12.13 / 23.76
Industry Med.27.54
Intrinsic Value Models
DCF (FCF Based)
$213.42
Median P/S Value
$221.73
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | 17.01 | 16.92 | 16.98 | 16.42 | 39.11 | At Loss | At Loss | 20.16 | 14.24 | At Loss | At Loss | |
| PS Ratio | 4.53 | 5.10 | 4.01 | 3.97 | 3.95 | 2.46 | 2.72 | 2.31 | 2.00 | 2.43 | 3.43 | |
| PB Ratio | 3.47 | 2.97 | 2.59 | 2.69 | 2.53 | 1.98 | 3.26 | 2.05 | 1.82 | 2.42 | 3.37 | |
| EV/EBITDA | 11.47 | 13.22 | 9.58 | 10.12 | 14.37 | 18.67 | 27.53 | 9.64 | 7.77 | 50.95 | 26.44 | |
| EV/Revenue | 5.46 | 5.59 | 4.18 | 4.20 | 3.97 | 4.33 | 4.10 | 3.08 | 2.61 | 3.15 | 4.02 |
Analyst Estimates & Quality
Altman Z-Score
1.97
Grey Zone
Piotroski F-Score
5
Moderate
Beneish M-Score
-2.38
Unlikely Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $4,515M | $4,829M | $5,261M |
| Net Income | $1,689M | $1,737M | $1,985M |
| EPS | 13.26 | 14.47 | 19.79 |
| Book Value per Share | 84.99 | 106.85 | 129.44 |
| Operating Cash Flow per Share | 23.45 | 26.09 | 33.83 |
| Operating CF | $1,549.88M | $1,724.71M | $2,236.38M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Identification, development and commercialization of meaningful pharmaceutical products that address | $4.27B |
By Geography
| Segment | 2025 |
|---|---|
| United States | $3.83B |
| All other | $94.9M |
| Europe | $341.1M |